Controlled release of NFκB decoy oligonucleotides from biodegradable polymer microparticles
Source abstract
Abstract
The objective of this study was to evaluate a poly(DL-lactic-co-glycolic acid)/poly(ethylene glycol) (PLGA/PEG) delivery system for nuclear factor-kappa B (NFkappaB) decoy phosphorothioated oligonucleotides (ODNs). PLGA/PEG microparticles loaded with ODNs were fabricated with entrapment efficiencies up to 70%. The effects of PEG contents (0, 5, and l0 wt%), ODN loading densities (0.4, 4, and 40 microg/mg), and pH of the incubation medium (pH 5, 7.4. and 10) on ODN release kinetics from the PLGA/PEG microparticles were investigated in vitro for up to 28 days. The release profiles in pH 7.4 phosphate buffered saline (PBS) were characterized by an initial burst during the first 2 days, a linear release phase until day 18, and a final release phase for the rest of the period. Up to 85% of the ODNs were released after 28 days in pH 7.4 PBS regardless of the ODN loading density and PEG content. Higher ODN loading densities resulted in lower entrapment efficiencies and greater initial burst effects. The bulk degradation of PLGA was not significantly affected by the PEG content and ODN loading density, but significantly accelerated at acidic buffer pH. Under acidic and basic conditions, the aggregation of microparticles resulted in significantly lower cumulative mass of released ODNs than that released at neutral pH. The effects of pH were reduced by the incorporation of PEG into PLGA microparticles. Since the PLGA degradation products are acidic, PLGA/PEG microparticles might provide a better ODN delivery vehicle than PLGA microparticles. These results suggest that PLGA/PEG microparticles are useful as delivery vehicles for controlled release of ODNs and merit further investigation in cell culture and animal models of glioblastoma.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: RNA Interference and Gene Delivery · NF-κB Signaling Pathways · Advanced Drug Delivery Systems
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (45)
Show source-provided references
1. Radiosurgery as part of the initial management of patients with malignant gliomas10.1200/JCO.1992.10.9.1379 ↗
2. Prognostic implications of p53 protein, epidermal growth factor receptor, and Ki-67 labelling in brain tumours10.1038/bjc.1992.273 ↗
3. Amplification and overexpression of the MDM2 gene in a subset of human malignant gliomas without p53 mutations
4. Accumulation of wild type p53 protein in human astrocytomas
5. Prognostic significance of p53 immunoreactivity in adult patients with supratentorial fibrillary astrocytic neoplasms10.1097/00019606-199412000-00005 ↗
6. A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity10.1073/pnas.91.16.7727 ↗
7. Alterations of the TP53 gene in human gliomas
8. The molecular biology and molecular genetics of astrocytic neoplasms
9. Prognostic factors in malignant glioma10.1023/A:1005841520514 ↗
10. MXI1, a putative tumor suppressor gene, suppresses growth of human glioblastoma cells
11. Kappa B site-dependent induction of gene expression by diverse inducers of nuclear factor kappa B requires Raf-110.1016/S0021-9258(17)46756-1 ↗
12. Function and activation of NF-kappa B in the immune system10.1146/annurev.iy.12.040194.001041 ↗
13. Highly expressed p100/p52 (NFKB2) sequesters other NF-kappa B-related proteins in the cytoplasm of human breast cancer cells
14. Bcl-2 suppresses apoptosis resulting from disruption of the NF-kappa B survival pathway10.1006/excr.1997.3737 ↗
15. Aberrant nuclear factor-kappaB/Rel expression and the pathogenesis of breast cancer10.1172/JCI119848 ↗
16. Characterization of an immediate-early gene induced in adherent monocytes that encodes I kappa B-like activity10.1016/0092-8674(91)90022-Q ↗
17. The I kappa B proteins10.1101/gad.7.11.2064 ↗
18. The I kappa B proteins10.1016/0168-9525(93)90106-R ↗
19. Rel/NF-kappa B/I kappa B family10.1101/gad.9.22.2723 ↗
20. NF-kappa B10.1016/S0092-8674(00)81318-5 ↗
21. Ceramide initiates NFkappaB-mediated caspase activation in neuronal apoptosis10.1006/nbdi.2000.0312 ↗
22. In vivo gene delivery to tumor cells by transferrin-streptavidin-DNA conjugate10.1096/fj.99-1052com ↗
23. Inhibition of smooth muscle cell growth in vitro by an antisense oligodeoxynucleotide released from poly(DL-lactic-co-glycolic acid) microparticles10.1002/(SICI)1097-4636(19970615)35:4<525::AID-JBM12>3.0.CO;2-A ↗
24. Controlled delivery systems for proteins based on poly(lactic/glycolic acid) microspheres10.1023/A:1015841715384 ↗
25. Poly(alpha-hydroxy acids)10.1016/0142-9612(96)85763-2 ↗
26. Protein delivery from poly(lactic-co-glycolic acid) biodegradable microspheres10.3109/02652049809008253 ↗
27. Delivering neuroactive molecules from biodegradable microspheres for application in central nervous system disorders10.1016/S0142-9612(98)00172-0 ↗
28. Controlled release of transforming growth factor beta1 from biodegradable polymer microparticles10.1002/(SICI)1097-4636(20000605)50:3<440::AID-JBM19>3.0.CO;2-G ↗
29. Effects of transforming growth factor beta1 released from biodegradable polymer microparticles on marrow stromal osteoblasts cultured on poly(propylene fumarate) substrates10.1002/(SICI)1097-4636(20000605)50:3<452::AID-JBM20>3.0.CO;2-0 ↗
30. Biodegradable polymers for cell transplantation
31. Development of a sustained-release biodegradable polymer delivery system for site-specific delivery of oligonucleotides10.3109/10611869808995882 ↗
32. Gill JS, Zhu X, Moore MJ, Lu L, Yaszemski MJ, Windebank AJ. Effects of NFkB decoy oligonucleotides released from biodegradable polymer microparticles on a glioblastoma cell line. Biomaterials, in press.
33. Synthetic biodegradable polymers for medical applications
34. Biodegradation and biocompatibility of PLA and PLGA microspheres10.1016/S0169-409X(97)00048-3 ↗
35. In vitro degradation of porous poly(L-lactic acid) foams10.1016/S0142-9612(00)00048-X ↗
36. In vitro and in vivo degradation of porous poly(DL-lactic-co-glycolic acid) foams10.1016/S0142-9612(00)00047-8 ↗
37. Microparticles of poly(DL-lactic-co-glycolic acid)/poly(ethylene glycol) blends for controlled drug delivery10.1016/S0168-3659(97)00052-7 ↗
38. Determinants of release rate of tetanus vaccine from polyester microspheres10.1023/A:1018942118148 ↗
39. Preparation and in vitro evaluation of polylactic acid-mitomycin C microcapsules10.3109/02652048609031572 ↗
40. Interstitial pH and pO2 gradients in solid tumors in vivo10.1038/nm0297-177 ↗
41. Purification of synthetic DNA10.1016/0076-6879(92)11004-3 ↗
42. The effects of polyethylene glycol 400 on gastrointestinal transit10.1023/A:1010927026837 ↗
43. Improvement of the encapsulation efficiency of oligonucleotide-containing biodegradable microspheres10.1016/S0168-3659(00)00299-6 ↗
44. The effect of pH on the in vitro degradation of poly(glycolide lactide) copolymer absorbable sutures10.1002/jbm.820160204 ↗
45. A theoretical model of erosion and macromolecular drug release from biodegrading microspheres10.1021/js9604117 ↗